NCT05627115 (RATiFY) is a Phase 2 clinical trial of Tislelizumab, AVD, Radiotherapy in Hodgkin Lymphoma, sponsored by University College, London.

Who is sponsoring NCT05627115?

NCT05627115 is sponsored by University College, London.

What drugs are being tested in NCT05627115?

Interventions in NCT05627115: Tislelizumab, AVD, Radiotherapy.

What condition does NCT05627115 study?

NCT05627115 studies Hodgkin Lymphoma.

Is NCT05627115 still recruiting?

NCT05627115 is currently not yet recruiting. Last updated 29 November 2023.

Last reviewed 2023-11-29 · How we verify

NCT05627115: RATiFY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma

Not yet recruiting Phase 2 Last updated 29 November 2023

What this trial tests

Phase 2 trial testing Tislelizumab, AVD, Radiotherapy in Hodgkin Lymphoma in 80 participants. Not yet recruiting.

Timeline

1 March 2024

Primary endpoint
1 October 2028

1 October 2028

Quick facts

Lead sponsor	University College, London
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 March 2024
Primary completion	1 October 2028
Estimated completion	1 October 2028

Drugs / interventions tested

Tislelizumab, AVD, Radiotherapy — full drug profile →

Conditions studied

Hodgkin Lymphoma — all drugs for Hodgkin Lymphoma →

Sponsor

University College, London

Who can join

60 and older, any sex, with Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test the effect of tislelizumab treatment in patients with Hodgkin lymphoma. The main question it aims to answer is whether including a drug called tislelizumab in first-line treatment of Hodgkin lymphoma for patients age 60 years and older is effective and well-tolerated. Participants will initially receive tislelizumab infusion every 21 days for 3 doses. After this a PET scan will be performed to assess the response. The subsequent treatment patients receive will depend on the following factors: 1. The lymphoma stage (early stage or advanced stage) 2. The presence or absence of specific high-risk features at the time of diagnosis 3. How well the lymphoma responds to the initial 3 doses of tislelizumab

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Hodgkin lymphoma treatment for older persons in the modern era.
Evens AM, McKenna M, Ryu Tiger YK, Upshaw JN. · · 2023 · cited 14× · PMID 38066840 · DOI 10.1182/hematology.2023000449
Recent Updates of PET in Lymphoma: FDG and Beyond.
Kim SY, Chung HW, So Y, Lee MH, et al · · 2024 · cited 2× · PMID 39595051 · DOI 10.3390/biomedicines12112485
Management of limited-stage Hodgkin lymphoma.
Al-Juhaishi T, Ahmed S. · · 2023 · cited 2× · PMID 38066938 · DOI 10.1182/hematology.2023000511

Verify or expand the search:

Other recruiting trials for Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
NCT07002216 — BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma · Phase 2 · recruiting

Other University College, London trials

Trials by the same sponsor.

NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05627115 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University College, London
Last refreshed: 29 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05627115.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing